Overview

Newly Diagnosed Glioblastoma

Status:
Recruiting

Trial end date:
2023-10-31

Target enrollment:

Participant gender:

Summary

Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma.Take PFS as the main evaluation index, the purpose is to evaluate its effectiveness

Phase:

Phase 2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Temozolomide